Quince Therapeutics (QNCX) Projected to Post Earnings on Wednesday

Quince Therapeutics (NASDAQ:QNCX) will likely be announcing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($1.5580) per share for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Quince Therapeutics Stock Performance

Quince Therapeutics stock opened at $1.23 on Wednesday. The stock has a market capitalization of $20.05 million, a price-to-earnings ratio of -0.07 and a beta of 1.45. Quince Therapeutics has a 52-week low of $0.80 and a 52-week high of $45.50. The stock’s 50 day moving average price is $1.16 and its two-hundred day moving average price is $15.43.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on QNCX shares. D. Boral Capital cut Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Maxim Group cut Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Lucid Cap Mkts cut Quince Therapeutics from a “strong-buy” rating to a “strong sell” rating in a report on Friday, January 30th. Wall Street Zen lowered Quince Therapeutics to a “strong sell” rating in a research report on Saturday, April 18th. Finally, Weiss Ratings lowered Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Five investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $65.00.

Institutional Investors Weigh In On Quince Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of QNCX. XTX Topco Ltd purchased a new stake in Quince Therapeutics in the 2nd quarter valued at $37,000. Nantahala Capital Management LLC purchased a new stake in Quince Therapeutics in the 2nd quarter valued at $4,172,000. Bridgeway Capital Management LLC raised its position in Quince Therapeutics by 20.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after buying an additional 22,200 shares during the last quarter. Vanguard Group Inc. raised its position in Quince Therapeutics by 21.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,763,387 shares of the company’s stock valued at $2,874,000 after buying an additional 309,349 shares during the last quarter. Finally, ADAR1 Capital Management LLC raised its position in Quince Therapeutics by 442.1% in the 3rd quarter. ADAR1 Capital Management LLC now owns 775,034 shares of the company’s stock valued at $1,263,000 after buying an additional 632,076 shares during the last quarter. 30.75% of the stock is owned by hedge funds and other institutional investors.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.